ANI Pharmaceuticals reported $290.77M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
ANI Pharmaceuticals USD 290.77M 24.77M Sep/2026
Aurora Cannabis CAD 67.55M 29.54M Jun/2026
Canopy Growth CAD 81.16M 9.91M Jun/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 15.03B 1.92B Sep/2026
Perrigo USD 989M 31M Sep/2026
Sun Pharmaceuticals INR 161.99B 8.99B Sep/2026
Teva Pharmaceutical Industries USD 4.37B 8.3B Sep/2026